Eloxx Pharmaceuticals Inc (ELOX)

Currency in USD
12.045
+0.295(+2.51%)
Closed·
11.5300.000(0.00%)
·
ELOX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
10.10912.910
52 wk Range
0.00017.500
Key Statistics
Prev. Close
11.75
Open
10.62
Day's Range
10.109-12.91
52 wk Range
0-17.5
Volume
28.34K
Average Volume (3m)
17.1K
1-Year Change
1,094,900%
Book Value / Share
-16.45
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ELOX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Eloxx Pharmaceuticals Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
May 05, 2026
EPS / Forecast
-0.08 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ELOX Income Statement

Compare ELOX to Peers and Sector

Metrics to compare
ELOX
Peers
Sector
Relationship
P/E Ratio
−6.0x−11.9x−0.4x
PEG Ratio
-−0.050.00
Price/Book
−6.4x3.5x2.6x
Price / LTM Sales
-2.9x3.0x
Upside (Analyst Target)
-52.8%57.0%
Fair Value Upside
Unlock−11.9%9.1%Unlock

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for the treatment of rare skin diseases, such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations. Eloxx Pharmaceuticals, Inc. was incorporated in 1999 and is based in Arlington, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
0.000.00%0.00
Other Institutional Investors
3.22M79.66%38.73M
Public Companies & Retail Investors
821.07K20.34%9.89M
Total
4.04M100.00%48.62M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
EcoR1 Capital, LLC10.00%403,5864,861
Artal Group S.A.9.91%400,0004,818

People Also Watch

97.30
ECHO
+0.11%
96.60
MXL
+2.25%
11.18
XNDU
-8.44%
5.980
RXT
-5.97%
9.3100
ASTC
-6.90%

FAQ

What Is the Eloxx Pharma (ELOX) Stock Price Today?

The Eloxx Pharma stock price today is 12.045 USD.

What Stock Exchange Does Eloxx Pharma Trade On?

Eloxx Pharma is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Eloxx Pharma?

The stock symbol for Eloxx Pharma is "ELOX."

What Is the Eloxx Pharma Market Cap?

As of today, Eloxx Pharma market cap is 48.620M USD.

What Is Eloxx Pharma's Earnings Per Share (TTM)?

The Eloxx Pharma EPS (TTM) is -3.772.

From a Technical Analysis Perspective, Is ELOX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Eloxx Pharma Stock Split?

Eloxx Pharma has split 4 times.

How Many Employees Does Eloxx Pharma Have?

Eloxx Pharma has 10 employees.

What is the current trading status of Eloxx Pharma (ELOX)?

As of Jun 29, 2026, Eloxx Pharma (ELOX) is trading at a price of 12.045 USD, with a previous close of 11.750 USD. The stock has fluctuated within a day range of 10.109 USD to 12.910 USD, while its 52-week range spans from 0.000 USD to 17.500 USD.

What Is the ELOX Premarket Price?

ELOX's last pre-market stock price is 11.610 USD. The pre-market share volume is 80.000, and the stock has decreased by -0.140, or -1.190%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.